The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Cellular therapy modalities being explored for the prevention of post-transplant relapse
Tania Jain, MBBS, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University, Baltimore, MD, provides an insight into the potential cellular therapy modalities being explored for the prevention of post-transplant relapse in hematological malignancies, outlining three main concepts being developed and investigated (tumor-associated antigen-targeting T-cells, HA1- and HA2-targeting T-cells, and gamma delta T-cells). Although patients with myelofibrosis (MF) are not yet included in early-phase clinical trials of these constructs, Dr Jain is hopeful that the concepts will soon be applied to the field of myeloproliferative neoplasms (MPNs) to improve outcomes of patients. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Institutional research support from CTI Biopharma, Kartos therapeutics, Incyte, Bristol Myers Squibb, Tscan; Advisory board participation with Bristol Myers Squibb, Incyte, Abbvie, CTI, Kite, Cogent Biosciences, Blueprint Medicine, Telios pharma, Protagonist therapeutics, Galapagos, Tscan therapeutics, Karyopharm, Morphosys, In8Bio.
